Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EDSA 
Edesa Biotech Inc (EDSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: EDSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.33
1 Year Target Price $10.33
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.99% | Avg. Invested days 33 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.64M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 1 | Beta 0.07 | 52 Weeks Range 1.55 - 4.49 | Updated Date 10/13/2025 |
52 Weeks Range 1.55 - 4.49 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.22% | Return on Equity (TTM) -69.64% |
Valuation
Trailing PE - | Forward PE 0.17 | Enterprise Value 19172235 | Price to Sales(TTM) 120477.93 |
Enterprise Value 19172235 | Price to Sales(TTM) 120477.93 | ||
Enterprise Value to Revenue 128525.38 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 7341705 | Shares Floating 4237579 |
Shares Outstanding 7341705 | Shares Floating 4237579 | ||
Percent Insiders 28.72 | Percent Institutions 29.95 |
Upturn AI SWOT
Edesa Biotech Inc
Company Overview
History and Background
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases. Founded to address unmet needs in dermatology and other indications, it has focused on developing and clinical testing of their lead drug candidate.
Core Business Areas
- Dermatology: Development of non-invasive treatments for skin diseases such as atopic dermatitis. Lead drug candidate is a topical formulation in late stage clinical testing.
- Other Inflammatory Conditions: Exploration of drug candidates for other inflammatory and immune related diseases.
Leadership and Structure
The company has a management team with experience in drug development, clinical trials, and regulatory affairs. Organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Competitors: Various companies developing ARDS treatments (e.g., corticosteroids, anti-inflammatory drugs)
- EB05 (Vitacreme B12): EB05 is a monoclonal antibody being developed as a treatment for acute respiratory distress syndrome (ARDS). It is designed to reduce the overactive and dysfunctional host response that leads to morbidity and mortality in severe cases of COVID-19. Competitors include companies developing other ARDS treatments, such as corticosteroids and anti-inflammatory drugs. Market share data is not yet available due to the drug being in development.
- Market: ARDS, COVID-19 Complications
- Competitors: Companies selling topical corticosteroids and calcineurin inhibitors.
- EB01: EB01 (a topical formulation of a phosphodiesterase-4 (PDE4) inhibitor) is being developed as a treatment for chronic allergic contact dermatitis (ACD). Competitors include companies selling topical corticosteroids and calcineurin inhibitors for the treatment of ACD. Market share data is not yet available due to the drug being in development.
- Market: Chronic Allergic Contact Dermatitis
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant investment in drug development and clinical trials. Regulatory approvals are crucial for market entry, and intellectual property protection is vital.
Positioning
Edesa Biotech is a smaller company aiming to secure its market share by addressing unmet medical needs in dermatology and other inflammatory conditions. Competitive advantages could arise from novel therapies and successful clinical trial results.
Total Addressable Market (TAM)
The global market for dermatology treatments and ARDS therapeutics is multi-billion dollar. Edesa Biotech is positioning itself by focusing on specific subsegments with significant unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Small company size
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from larger companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LLY
- MRK
- SNY
Competitive Landscape
Edesa Biotech is a smaller player in a competitive market. To compete, they need to focus on differentiated therapies and address unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is mainly defined by progress of clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates can vary widely given uncertainty.
Recent Initiatives: Recent initiatives include advancing EB05 in ARDS clinical trials and progressing EB01 in allergy clinical trials.
Summary
Edesa Biotech is a clinical-stage biopharmaceutical company with potential in its drug candidates targeting inflammatory diseases. Its success hinges on positive clinical trial results and securing partnerships. The company faces the usual risks associated with drug development, including clinical trial failures and competition from larger, more established players. Careful management of finances and strategic execution of clinical programs are critical for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edesa Biotech Inc
Exchange NASDAQ | Headquaters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.edesabiotech.com |
Full time employees 16 | Website https://www.edesabiotech.com | ||
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.